Antiangiogenic strategies in medulloblastoma: Reality or mystery

Pediatric Research

Volumn 63, Issue 5, 2008, Pages 584-590

  Grizzi, Fabio ^a   Weber, Christina ^b   Di Ieva, Antonio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b Regional Hospital   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CEDIRANIB; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHILDHOOD CANCER; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDULLOBLASTOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION;

ADOLESCENT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; FRACTALS; HUMANS; INFANT; INFANT, NEWBORN; MEDULLOBLASTOMA; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 42449131040     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/01.pdr.0000305884.29279.6b     Document Type: Review

References (76)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ 2007 Cancer statistics, 2007. CA Cancer J Clin 57:43-66
2. Raffel C 2004 Medulloblastoma: molecular genetics and animal models. Neoplasia 6:310-322
3. Polkinghorn WR, Tarbell NJ 2007 Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4:295-304
4. Wright JH 1910 Neurocytoma or neuroblastoma, a kind of tumor not generally recognized. J Exp Med 12:556-561
5. Read TA, Hegedus B, Wechsler-Reya R, Gutmann DH 2006 The neurobiology of neurooncology. Ann Neurol 60:3-11
6. Humphreys RP 1983 Posterior cranial fossa brain tumors in children. In: Youmans JR (ed) Neurological Surgery. Saunders, Philadelphia, pp 2733-2752
7. Matsutani M 2004 Chemoradiotherapy for brain tumors: current status and perspectives. Int J Clin Oncol 9:471-474
8. Gilbertson RJ 2004 Medulloblastoma: signaling a change in treatment. Lancet Oncol 5:209-218
9. Eberhart CG, Kepner JL, Goldthwaite PT, Kun LE, Duffner PK, Friedman HS, Strother DR, Burger PC 2002 Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 94:552-560
10. Marino S 2005 Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 11:17-22
11. Grimmer MR, Weiss WA 2006 Childhood tumors of the nervous system as disorders of normal development. Curr Opin Pediatr 18:634-638
12. Collins VP 2004 Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 75:ii2-ii11
13. Bigner SH, McLendon RE, Fuchs H, McKeever PE, Friedman HS 1997 Chromosomal characteristics of childhood brain tumors. Cancer Genet Cytogenet 97:125-134
14. Bigner SH, Mark J, Friedman HS, Biegel JA, Bigner DD 1988 Structural chromosomal abnormalities in human medulloblastoma. Cancer Genet Cytogenet 30:91-101
15. Biegel JA, Burk CD, Barr FG, Emanuel BS 1992 Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res 52:3391-3395
16. Reardon DA, Michalkiewicz E, Boyett JM, Sublett JE, Entrekin RE, Ragsdale ST, Valentine MB, Behm FG, Li H, Heideman RL, Kun LE, Shapiro DN, Look AT 1997 Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res 57:4042-4047
17. James CD, He J, Carlbom E, Mikkelsen T, Ridderheim PA, Cavenee WK, Collins VP 1990 Loss of genetic information in central nervous system tumors common to children and young adults. Genes Chromosomes Cancer 2:94-102
18. Bayani J, Zielenska M, Marrano P, Kwan Ng Y, Taylor MD, Jay V, Rutka JT, Squire JA 2000 Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 93:437-448
19. Michiels EM, Weiss MM, Hoovers JM, Baak JP, Voute PA, Baas F, Hermsen MA 2002 Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J Pediatr Hematol Oncol 24:205-210
20. Reifenberger J, Wolter M, Weber RG, Megahed M, Ruzicka T, Lichter P, Reifenberger G 1998 Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 58:1798-1803
21. Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, Zhang X, Agatep R, Chiappa S, Gao L, Lowrance A, Hao A, Goldstein AM, Stavrou T, Scherer SW, Dura WT, Wainwright B, Squire JA, Rutka JT, Hogg D 2002 Mutations in SUFU predispose to medulloblastoma. Nat Genet 31:306-310
22. Herms J, Neidt I, Luscher B, Sommer A, Schurmann P, Schroder T, Bergmann M, Wilken B, Probst-Cousin S, Hernaiz-Driever P, Behnke J, Hanefeld F, Pietsch T, Kretzschmar HA 2000 C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 89:395-402
23. Grotzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, Eggert A, Sutton LN, Rorke LB, Brodeur GM, Phillips PC 2001 MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 7:2425-2433
24. MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y, Packer RJ, Cogen P, Stephan DA 2001 Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29:143-152
25. Gilbertson RJ, Clifford SC 2003 PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 35:197-198
26. Grizzi F, Di Ieva A, Russo C, Frezza EE, Cobos E, Muzzio PC, Chiriva-Internati M 2006 Cancer initiation and progression: an unsimplifiable complexity. Theor Biol Med Model 3:37
27. Reddy AT, Packer RJ 1999 Medulloblastoma. Curr Opin Neurol 12:681-685
28. Wechsler-Reya R, Scott MP 2001 The developmental biology of brain tumors. Annu Rev Neurosci 24:385-428
29. Zurawel RH, Allen C, Chiappa S, Cato W, Biegel J, Cogen P, de Sauvage F, Raffel C 2000 Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 27:44-51
30. Unden AB, Holmberg E, Lundh-Rozell B, Stähle-Bäckdahl M, Zaphiropoulos PG, Toftgård R, Vorechovsky I 1996 Mutations in the human homologue of Drosophila patched (PTCH) in basal cell carcinomas and the Gorlin syndrome: different in vivo mechanisms of PTCH inactivation. Cancer Res 56:4562-4565
31. Wetmore C, Eberhart DE, Curran T 2000 The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Cancer Res 60:2239-2246
32. Tong WM, Ohgaki H, Huang H, Granier C, Kleihues P, Wang ZQ 2003 Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice. Am J Pathol 162:343-352
33. Gilbertson RJ, Gajjar A 2005 Molecular biology of medulloblastoma: will it ever make a difference to clinical management? J Neurooncol 75:273-278
34. Verlooy J, Mosseri V, Bracard S, Tubiana AL, Kalifa C, Pichon F, Frappaz D, Chastagner P, Pagnier A, Bertozzi AI, Gentet JC, Sariban E, Rialland X, Edan C, Bours D, Zerah M, Le Gales C, Alapetite C, Doz F 2006 Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. Eur J Cancer 42:3004-3014
35. Palmer SL, Reddick WE, Gajjar A 2007 Understanding the cognitive impact on children who are treated for medulloblastoma. J Pediatr Psychol 32:1040-1049
36. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, Kellie SJ, Kun L, Gilbertson RJ 2004 Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22:984-993
37. Raffaghello L, Nozza P, Morandi F, Camoriano M, Wang X, Garre ML, Cama A, Basso G, Ferrone S, Gambini C, Pistoia V 2007 Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Res 67:5471-5478
38. Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S 2007 Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res 67:5957-5964
39. Carmeliet P 2005 Angiogenesis in life, disease and medicine. Nature 438:932-936
40. Fidler IJ, Ellis LM 2004 Neoplastic angiogenesis - not all blood vessels are created equal. N Engl J Med 351:215-216
41. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B 1998 Tumor induction of VEGF promoter activity in stromal cells. Cell 94:715-725
42. Tandle A, Blazer DG III, Libutti SK 2004 Antiangiogenic gene therapy of cancer: recent developments. J Transl Med 2:22
43. Gilhuis HJ, van der Laak JA, Pomp J, Kappelle AC, Gijtenbeek JM, Wesseling P 2006 Three-dimensional (3D) reconstruction and quantitative analysis of the microvasculature in medulloblastoma and ependymoma subtypes. Angiogenesis 9:201-208
44. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT 2007 Angiogenesis in brain tumours. Nat Rev Neurosci 8:610-622
45. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE 2001 Preferential susceptibility of brain tumors to the anti-angiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48:151-157
46. Brooks PC, Clark RA, Cheresh DA 1994 Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-571
47. Hynes RO 1987 Integrins: a family of cell surface receptors. Cell 48:549-554
48. Howe A, Aplin AE, Alahari SK, Juliano RL 1998 Integrin signaling and cell growth control. Curr Opin Cell Biol 10:220-231
49. Longhurst CM, Jennings LK 1998 Integrin-mediated signal transduction. Cell Mol Life Sci 54:514-526
50. Huber H, Eggert A, Janss AJ, Wiewrodt R, Zhao H, Sutton LN, Rorke LB, Phillips PC, Grotzer MA 2001 Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas. Eur J Cancer 37:2064-2072
51. Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA 2008 Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 50:581-587
52. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jurgensmeier JM, Ogilvie DJ 2005 AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400
53. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L 1999 Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 59:4770-4775
54. O'Reilly MS, Holmgren L, Chen C, Folkman J 1996 Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689-692
55. Grizzi F, Colombo P, Taverna G, Chiriva-Internati M, Cobos E, Graziotti P, Muzzio PC, Dioguardi N 2007 Geometry of human vascular system: is it an obstacle for quantifying anti-angiogenic therapies? Appl Immunohistochem Mol Morphol 15:134-139
56. Grizzi F, Russo C, Colombo P, Franceschini B, Frezza EE, Cobos E, Chiriva-Internati M 2005 Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension. BMC Cancer 5:14
57. Grizzi F, Colombo P, Barbieri B, Franceschini B, Roncalli M, Chiriva-Internati M, Muzzio PC, Dioguardi N 2001 Correspondence re: E. Sabo et al., Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. Clin Cancer Res 7:533-537. Clin Cancer Res 7:3305-3307
58. Di Ieva A, Grizzi F, Ceva-Grimaldi G, Russo C, Gaetani P, Aimar E, Levi D, Pisano P, Tancioni F, Nicola G, Tschabitscher M, Dioguardi N, Baena RR 2007 Fractal dimension as a quantitator of the microvasculature of normal and adenomatous pituitary tissue. J Anat 211:673-680
59. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B 2007 Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11:539-554
60. Jain RK, Schlenger K, Hockel M, Yuan F 1997 Quantitative angiogenesis assays: progress and problems. Nat Med 3:1203-1208
61. Harris AL 2002 Hypoxia - a key regulatory factor in tumor growth. Nat Rev Cancer 2:38-47
62. Munn LL 2003 Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 8:396-403
63. Stergiopulos N, Porret CA, De Brouwer S, Meister JJ 1998 Arterial vasomotion: effect of flow and evidence of nonlinear dynamics. Am J Physiol 274:H1858-H864
64. Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O, Schwarzinger I 2004 Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 351:250-259
65. Hlatky L, Hahnfeldt P, Folkman J 2002 Clinical application of anti-angiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94:883-893
66. Grotzer MA, Wiewrodt R, Janss AJ, Zhao H, Cnaan A, Sutton LN, Rorke LB, Phillips PC 2001 High microvessel density in primitive neuroectodermal brain tumors of childhood. Neuropediatrics 32:75-79
67. Miralbell R, Tolnay M, Bieri S, Probst A, Sappino AP, Berchtold W, Pepper MS, Pizzolato G 1999 Pediatric medulloblastoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density. J Neurooncol 45:103-110
68. Ozer E, Sarialioglu F, Cetingoz R, Yuceer N, Cakmakci H, Ozkal S, Olgun N, Uysal K, Corapcioglu F, Canda S 2004 Prognostic significance of anaplasia and angiogenesis in childhood medulloblastoma: a pediatric oncology group study. Pathol Res Pract 200:501-509
69. Pavlakovic H, Von Schutz V, Rossler J, Koscielniak E, Havers W, Schweigerer L 2001 Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer 92:756-760
70. Folkerth RD 2000 Descriptive analysis and quantification of angiogenesis in human brain tumors. J Neurooncol 50:165-172
71. Hogan BL, Kolodziej PA 2002 Organogenesis: molecular mechanisms of tubulogenesis. Nat Rev Genet 3:513-523
72. Lubarsky B, Krasnow MA 2003 Tube morphogenesis: making and shaping biological tubes. Cell 112:19-28
73. Parker LH, Schmidt M, Jin SW, Gray AM, Beis D, Pham T, Frantz G, Palmieri S, Hillan K, Stainier DY, De Sauvage FJ, Ye W 2004 The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature 428:754-758
74. Bertolini F, Mancuso P, Shaked Y, Kerbel RS 2007 Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today 12:806-812
75. Aird WC 2007 Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 100:158-173
76. Yano K, Gale D, Massberg S, Cheruvu PK, Monahan-Earley R, Morgan ES, Haig D, von Andrian UH, Dvorak AM, Aird WC 2007 Phenotypic heterogeneity is an evolutionarily conserved feature of the endothelium. Blood 109:613-615